These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com. In addition, clinical data to date provide evidence that these observations are being borne out in patients. Presentation Details: Abstract title: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: New mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumorsPresenting author: Antoine Tanne, PhD Abstract title: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimabPresenting author: Irina Shapiro, PhD About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. Kids crossing by themselves rose 60% to more than 9,400, forcing the government to look for new places to hold them temporarily. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Russell 2000 is up 310.83 points, or 15.7%. Culp said the deal would “de-risk” GE, in part by reducing debt, yet S&P Global Ratings warned of financial threats that could prompt a downgrade.The AerCap deal carries potential weaknesses. "No, it would have been nice to know that at the time," he replied. The company maintained its 2021 financial forecast, predicting adjusted earnings of 15 to 25 cents a share. Presentation Type: e-poster (Abstract: 1607)Title: IL-27 signaling serves as an immunological checkpoint for NK cells to promote hepatocellular carcinoma in multiple murine modelsLead Author: Turan Aghayev Summary: SRF388 is a fully human antibody designed to inhibit the immunosuppressive activity of IL-27.IL-27 signaling suppresses natural killer (NK) cells within the tumor microenvironment, promoting hepatocellular carcinoma (HCC) development in vivo.Elevated IL-27RA expression in cancer tissue and elevated EBI3 serum levels are associated with poor prognosis in patients with HCC.Inhibiting IL-27 signaling leads to tumor growth inhibition and suppressed HCC development in a non-alcoholic steatohepatitis (NASH)-driven HCC model with concomitant enhancement of NK cell activity.These findings indicate that IL-27 blockade regulates NK cell-mediated control of HCC and is a promising therapeutic target in liver cancer. Driving the increase is widespread hunger in Central America due to recent hurricanes, the economic upheaval of the pandemic and more fundamental social problems dating back years. MFG. The lingering pain for aircraft financiers raises doubts about whether bigger is better, even as AerCap said the deal would position it to profit over time as air travel recovers.“Even if an AerCap-Gecas combination improves the cost of debt, which is essential to be more competitive, aircraft leasing will remain highly challenged, with companies from Asia gaining clout due to a lower cost of capital and local influence,” Bloomberg Intelligence analysts George Ferguson and Francois Duflot said in a report. These forward-looking statements are based on Surface Oncology’s management’s current beliefs and assumptions about future events and on information currently available to management. Ben Fox, The Associated Press. POWER PKG - REC. This can also be used for landscaping and backfilling drains. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study.